WEST BRIDGEWATER, Mass. — Theromics Inc. has appointed Andrew C. Zeringue as chief executive officer, bringing in a medtech executive with nearly two decades of experience in interventional oncology, thermal ablation and the commercialization of medical technologies.
The West Bridgewater-based company is developing ablation therapeutics for minimally invasive cancer treatment. Zeringue has worked with emerging technologies from FDA clearance through early commercialization and broader market adoption.
“We reviewed many candidates for this position and Andrew’s extensive experience in interventional oncology and thermal ablation quickly distinguished him as the right choice to steer Theromics into its next chapter,” said Joseph Amaral, M.D., Chairman of the Board of Theromics. “Under Andrew’s leadership we are confident the company is well positioned to advance its platform technologies toward commercialization and deliver innovative solutions that help physicians address cancer treatment challenges, including reducing the risk of local cancer recurrence.”
Theromics is developing biomaterial technologies designed to support more predictable energy delivery and improved treatment consistency in minimally invasive cancer therapies. Its work includes technologies intended to address local tumor recurrence following ablation procedures.
The company is advancing its HeatSYNC gel platform, which is designed to enhance thermal energy transfer within soft tissue during ablation procedures, toward FDA clearance and clinical adoption.
Zeringue has held senior leadership roles at Quantum Surgical, NeuWave Medical, BTG and AngioDynamics, all companies involved in interventional oncology or thermal ablation technologies. NeuWave Medical became part of Ethicon, a Johnson & Johnson subsidiary, while BTG was acquired by Boston Scientific.
During his career, Zeringue has helped scale multiple first-in-category platforms and has worked with physicians, academic medical centers, health systems and executive leadership teams to bring emerging technologies into clinical use. He is also co-founder of MedTech Angels, a physician- and operator-led investment group focused on early-stage FDA-regulated medical device companies.
“I believe Theromics is uniquely positioned to help advance the next generation of local tumor therapy,” said Andrew C. Zeringue. “Local recurrence following minimally invasive cancer treatment remains a significant clinical challenge, and Theromics is developing technologies designed to support more effective and predictable therapy delivery. The company’s founders are internationally recognized thought leaders in interventional oncology, and I am honored to join them in their mission to reduce recurrences following ablation therapy through the field of ablation therapeutics.”
